Keros Therapeutics, Inc.KROSEarnings & Financial Report
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for hematological disorders, musculoskeletal diseases and anemia, serving underserved patient groups with unmet medical needs from its core U.S. base.
Revenue
$8.0K
Gross Profit
N/A
Operating Profit
$-43.3M
Net Profit
$-39.4M
Gross Margin
N/A
Operating Margin
-541000.0%
Net Margin
-493000.0%
YoY Growth
N/A
EPS
$-1.33
Keros Therapeutics, Inc. Q3 FY2023 Financial Summary
Keros Therapeutics, Inc. reported revenue of $8.0K for Q3 FY2023, with a net profit of $-39.4M (down 67.8% YoY) (-493000.0% margin).
Key Financial Metrics
| Total Revenue | $8.0K |
|---|---|
| Net Profit | $-39.4M |
| Gross Margin | N/A |
| Operating Margin | -541000.0% |
| Report Period | Q3 FY2023 |
Keros Therapeutics, Inc. Annual Revenue by Year
Keros Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $244.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $244.1M |
Keros Therapeutics, Inc. Quarterly Revenue & Net Profit History
Keros Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $385.0K | -87.3% | N/A | N/A |
| Q3 FY2025 | $14.3M | +3575.8% | $-7.3M | -51.0% |
| Q2 FY2025 | $18.2M | +49002.7% | $-30.7M | -169.0% |
| Q1 FY2025 | $211.2M | +254413.3% | $148.5M | 70.3% |
| Q3 FY2024 | $388.0K | +4750.0% | $-53.0M | -13648.5% |
| Q2 FY2024 | $37.0K | — | $-45.3M | -122316.2% |
| Q1 FY2024 | $83.0K | — | $-43.1M | -51944.6% |
| Q3 FY2023 | $8.0K | — | $-39.4M | -493000.0% |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8000 | $83000 | $37000 | $388000 | $211.2M | $18.2M | $14.3M | $385000 |
| YoY Growth | N/A | N/A | N/A | 4750.0% | 254413.3% | 49002.7% | 3575.8% | -87.3% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $326.2M | $485.8M | $455.0M | $579.3M | $784.6M | $757.2M | $742.8M | $338.0M |
| Liabilities | $30.4M | $31.9M | $34.1M | $46.4M | $55.7M | $50.4M | $39.2M | $34.9M |
| Equity | $295.8M | $453.9M | $420.9M | $532.8M | $728.9M | $706.7M | $703.6M | $303.1M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-34.0M | $-44.6M | $-39.8M | $-30.5M | $161.2M | $-29.6M | $3.2M | $107.5M |